Furthermore, it will be of interesting to assess XPc therapeutic potential in G6PD-deficient patients as proposed for AG1 and its derivatives [32,33,55] as well as in the predisposed metabolic syndrome patients. The gene discussed is G6PD; the disease is metabolic syndrome.